Neuropeptide Y (NPY) receptors belong to the G-protein-coupled receptor superfamily and have important roles in food intake, anxiety and cancer biology 1,2 . The NPY-Y receptor system has emerged as one of the most complex networks with three peptide ligands (NPY, peptide YY and pancreatic polypeptide) binding to four receptors in most mammals, namely the Y 1 , Y 2 , Y 4 and Y 5 receptors, with different affinity and selectivity 3 . NPY is the most powerful stimulant of food intake and this effect is primarily mediated by the Y 1 receptor (Y 1 R) 4 . A number of peptides and small-molecule compounds have been characterized as Y 1 R antagonists and have shown clinical potential in the treatment of obesity 4 , tumour 1 and bone loss 5 . However, their clinical usage has been hampered by low potency and selectivity, poor brain penetration ability or lack of oral bioavailability 6 . Here we report crystal structures of the human Y 1 R bound to the two selective antagonists UR-MK299 and BMS-193885 at 2.7 and 3.0 Å resolution, respectively. The structures combined with mutagenesis studies reveal the binding modes of Y 1 R to several structurally diverse antagonists and the determinants of ligand selectivity. The Y 1 R structure and molecular docking of the endogenous agonist NPY, together with nuclear magnetic resonance, photo-crosslinking and functional studies, provide insights into the binding behaviour of the agonist and for the first time, to our knowledge, determine the interaction of its N terminus with the receptor. These insights into Y 1 R can enable structure-based drug discovery that targets NPY receptors.
Letter reSeArCH Y 1 R antagonist was confirmed by the NPY-induced inositol phosphate accumulation of Y 1 R when inhibited by UR-MK299 and several related Y 1 R antagonists-BIBP3226, BIBO3304, UR-HU404 and UR-MK289 (Extended Data Fig. 1e -i). The F302 7. 35 A mutation abolishes the antagonistic activity for all these antagonists, and a two-to fivefold decrease in the antagonistic effect of all tested antagonists was observed for the F286 6 .58 A mutation ( Fig. 3a -c, Extended Data Fig. 2 and Extended Data Table 2 ).
The hydroxyphenyl group of UR-MK299 sits in a groove formed by helices III and VI of the receptor, enabling hydrophobic contacts with residues Q120 3.32 , C121 3.33 , I124 3.36 , W276 6.48 and L279 6.51 . In Y 1 R and Y 2 R, Q120 3.32 is suggested to be the interaction partner for the C terminus of NPY and crucial for receptor activation 16 . In the Y 1 R-UR-MK299 structure, this residue forms a hydrophobic contact with the phenyl ring of the hydroxyphenyl group in UR-MK299, potentially blocking the binding of Y 1 R to NPY. Mutagenesis data show that the Q120 3.32 N mutation does not influence the inhibitory effect of Y 1 R antagonists on NPY signalling, but a mutation to histidine increases the antagonistic activity of these ligands (Fig. 3d , e and Extended Data Table 2 ), suggesting that an additional π-stacking interaction with the antagonist is beneficial at this position. The highly conserved residue W 6.48 represents the 'toggle switch' and was suggested to trigger receptor activation through a conformational change in various GPCRs 17 . In the Y 1 R-UR-MK299 structure, the residue W276 6.48 is in a conformation that is similar to those observed in other inactive class A GPCR structures and is distinct from their active-state conformations 18, 19 . The hydroxyphenyl group of UR-MK299 forms a hydrophobic contact with W276 6.48 , potentially preventing its activation-related motion thus stabilizing the receptor in an inactive conformation. Compared to the wild-type receptor, the Y 1 R mutant W276 6.48 A displayed an over 2,000-fold decrease in its binding affinity to [ 3 H]UR-MK299 (Extended Data Table 3 ) and reduced the antagonistic activity of the argininamide-type Y 1 R antagonists by four-to sevenfold ( Fig. 3f and Extended Data Table 2 ), supporting its important role in antagonist recognition.
Residues N283 6.55 and D287 6.59 were suggested as the most important amino acids for Y 1 R ligand recognition 20 . In the Y 1 R-UR-MK299 structure, N283 6.55 is engaged in two hydrogen bonds with the α-nitrogen and the carboxylic oxygen next to the hydroxybenzylamine moiety of UR-MK299. D287 6.59 builds a salt bridge with the protonated guanidinyl moiety and a hydrogen bond with the carbamoyl group, in agreement with a decrease in antagonist affinity when the carbamoyl group was replaced by an alkoxycarbonyl, acyl or alkyl group 21 . The mutants N283 6.55 A and D287 6.59 N displayed a notable loss of NPYinduced receptor function, a complete abolishment of antagonistic activity for the small-molecule antagonists (Fig. 3g , h and Extended Data Table 2), and an over 2,000-fold decrease in the binding affinity of Y 1 R to [ 3 H]UR-MK299 (Extended Data Table 3 ). These data indicate the critical roles of these two residues in agonist and antagonist binding. Additionally, the carbamoyl substituent at the guanidine group binds deep in a sub-pocket shaped by helices V and VI, characterized by hydrophobic contacts with L216 5.43 , T280 6.52 and N283 6.55 , and a hydrogen bond between the oxygen of the propionyl group and Q219 5. 46 . The latter was reflected by a 30-fold decrease in the binding affinity of [ 3 H] UR-MK299 to the Y 1 R mutants Q219 5. 46 A and Q219 5.46 V (Extended Data Table 3 ). Extra empty space at the bottom of the sub-pocket is observed in the Y 1 R-UR-MK299 structure, suggesting that a larger substituent may be allowed (Extended Data Fig. 1c ). This is supported by studies showing that other carbamoylated argininamide-type Y 1 R antagonists containing longer carbamoyl chains, such as UR-MK136 (Extended Data Fig. 1j ), bind to the receptor with a relatively high affinity 10 .
UR-MK299 was reported to exhibit high Y 1 R selectivity (Y 2 R, inhibition constant (K i ) > 3,000 nM; Y 4 R and Y 5 R, K i > 10,000 nM) and specificity compared to two related neuropeptide FF (NPFF) receptors (NPFF 1 R, K i = 1,000 nM; NPFF 2 R, K i > 3,000 nM) 10 . Sequence alignment reveals that most of the key residues involved in UR-MK299 binding are conserved between Y 1 R, the other NPY receptors and the NPFFRs, except for F 4.60 , Q 5. 46 , N 6.55 and F 6.58 (Extended Data Fig. 3 ), indicating the importance of these four residues in terms of the selectivity and specificity of UR-MK299. Y 2 R is the only NPY receptor with L 5. 46 instead of Q 5. 46 , preventing key polar contacts. In Y 4 R, E 6.58 disturbs the F 6.54 -F 6.58 -F 7.35 hydrophobic patch and probably mediates selectivity, supported by the F 6.58 E mutation in Y 1 R reducing binding affinity for BIBP3226 22 , which contains the same diphenylmethyl group as UR-MK299. Similarly, hydrophilic residues at key positions impede high-affinity binding at Y 5 R (T 6.58 ) and NPFF 2 R (S 6.58 ), while the hydrophobic pocket is preserved in NPFF 1 R (L 6.54 -I 6.58 -F 7.35 ), although with less bulk, leading to a moderate affinity of BIBP3226 (K i = 18 nM) 10 .
The ligands BMS-193885 and UR-MK299 occupy a similar binding pocket within the helical bundle of Y 1 R (Fig. 2c, d and Extended Data Fig. 1k ). The dihydropyridine group of BMS-193885 fits in a subpocket formed by helices III, V and VI, which aligns with previous structure-activity relationship studies showing that larger substituents at position three of the dihydropyridine ring reduced Y 1 R binding affinity 23 . Residue T280 6.52 forms a hydrogen bond with the nitrogen of the dihydropyridine ring as confirmed by our mutagenesis studies, which showed that the T280 6.52 A mutation decreased the binding affinity of BMS-193885 by about 330-fold (Extended Data Table 3 ), in agreement with a reported lower affinity N-methylated derivative 24 . Additionally, the dihydropyridine ring makes a hydrophobic contact with residue I124 3. 36 , which is consistent with a 400-fold decrease in BMS-193885 The receptor is shown in grey cartoon representation. UR-MK299 (yellow carbons) and receptor residues (dark brown carbons) involved in ligand binding are shown as sticks. Salt bridge and hydrogen bonds are shown as red and green dashed lines, respectively. b, Schematic representation of the interactions between Y 1 R and UR-MK299 analysed using the LigPlot + program 30 . The stick drawing of Y 1 R residues is coloured dark brown. c, Binding pocket for BMS-193885. BMS-193885 (pink carbons) and receptor residues (green carbons) involved in ligand binding are shown as sticks. d, Schematic representation of interactions between Y 1 R and BMS-193885 analysed using the LigPlot + program 30 . The stick drawing of Y 1 R residues is coloured green.
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the affinity of the mutant I124 3.36 A (Extended Data Table 3 ). It was also reported that methylation of either nitrogen of the urea group of BMS-193885 decreased the binding ability of the methylated derivatives to Y 1 R 24 , suggesting that these hydrogen bond donors are critical for Y 1 R recognition. Indeed, in the BMS-193885-bound Y 1 R structure, the urea group forms hydrogen bond interactions with D287 6.59 . Similar to the diphenylmethyl group of UR-MK299, the piperidine and methoxyphenyl rings of BMS-193885 form extensive hydrophobic contacts with the residues F282 6.54 , F286 6.58 and F302 7.35 . Replacement of the methoxyphenyl substituent by piperidine resulted in lower binding affinity to Y 1 R 23 , indicating the importance of the methoxyphenyl group in Y 1 R binding and reflecting lipophilic demands at this position.
Understanding the binding mode of the endogenous agonist NPY at a molecular level will facilitate the rational development of Y 1 Rselective ligands. The C-terminal pentapeptide of NPY was found to be essential for binding to the NPY receptors 25 . Because the hydroxyphenyl and the argininamide group of UR-MK299 mimic R35 and Y36 in the C terminus of NPY (Extended Data Fig. 1l ), the crystal structure of Y 1 R-UR-MK299 serves as a good template for molecular docking of the agonist. To aid docking, complementary mutagenesis studies were performed to determine corresponding interaction partners between Y 1 R and NPY (Extended Data Table 4a ). Furthermore, solid-state nuclear magnetic resonance (NMR) chemical shift measurements revealed residue-specific alterations of the secondary structure of NPY upon binding to Y 1 R (Extended Data Fig. 4 ). Several key Y 1 R-NPY contacts identified by the mutagenesis studies were used to guide NPY docking in Rosetta 26 with the final models being filtered against the NMR data to generate a final ensemble that best represents the combined data. The NPY-bound model reveals a relatively flat NPY-Y 1 R binding pose with the C-terminal tetrapeptide R33-Y36, identified as either a random coil or a β-strand structure in NMR, penetrating into the binding pocket ( Fig. 4a ). The unstructured N terminus (Y1-P13) is in close proximity to the second extracellular loop (ECL2), while the α-helix in the middle region of NPY (A14-T32) lies along ECL1 and ECL3 and points away from ECL2.
Inspection of the binding pocket of NPY reveals that the binding pose of residue R35 of NPY is similar to that of the argininamide of UR-MK299 ( Fig. 4b ). R35 forms a salt bridge with the D287 6.59 residue of Y 1 R and approaches N283 6.55 (Fig. 4c ). The NPY mutant R35A displays a decrease in activity of over 6,000-fold, which represents the highest influence on agonist potency of all tested NPY analogues (Extended Data Table 4a ), supporting the importance of the positively charged residue in NPY recognition. Aspartate or glutamate residues are not found at position 6.59 in any peptide GPCRs except for the receptors that bind to Arg-Phe-amide peptides, including NPFF, prolactin-releasing peptide and pyroglutamylated Arg-Phe-amide peptide, which share a common C-terminal Arg-Phe-NH 2 motif, supporting the hypothesis that the arginine residue may function in a manner that Letter reSeArCH is similar to that of the R35 of NPY by interacting with the conserved D/E 6.59 of the respective receptors 27 . In contrast to the similarity between the binding modes of the R35 of NPY and the guanidine group of UR-MK299, the C-terminal tyrosinamide of NPY and the hydroxyphenyl group of UR-MK299 show different orientations. The hydroxyphenyl ring is oriented towards helix V (Q219 5. 46 ) in the UR-MK299-bound Y 1 R structure, whereas Y36 of NPY points towards the Q120 3.32 residue on helix III in the NPY-docked model (Fig. 4c ). This may arise from the opposite configuration of the stereo centre in the R35 of NPY and UR-MK299, as well as by only partial mimicking of the Y36-NH 2 of NPY by a 4-hydroxybenzyl group in UR-MK299 (Extended Data Fig. 1g , l). In the Y 1 R-UR-MK299 structure, residue Q120 3.32 forms a hydrophobic contact with the hydroxyphenyl group of the antagonist. By contrast, the NPY-bound model shows that the side chain of Q120 3.32 points almost in the opposite direction and engages in a hydrogen bond with the hydroxy group of Y36-NH 2 (Extended Data Fig. 1d ), in a similar manner to the previously suggested interaction between the Y 2 R residue Q 3.32 and NPY 28 . In Y 2 R, it was also reported that Q 3.32 may interact with the C-terminal amide of NPY 16 . Inositol phosphate accumulation studies show that the Y 1 R mutation Q120 3.32 H leads to a 26-fold decrease in the potency of NPY, and NPY-tyramide lacking the C-terminal amide displays a 45-fold loss of activity. Complementary mutagenesis analysis revealed an additional reduction of NPY-tyramide potency at the Q120 3.32 H mutant, and thus rules out a direct contact between the C-terminal amide of NPY and Q120 3.32 in Y 1 R (Extended Data  Table 4a ). Additionally, Y36 of NPY forms hydrophobic contacts with Y100 2.64 and W106 ECL1 in Y 1 R (Fig. 4c ). Although Y100 2.64 is not involved in antagonist binding, mutagenesis data suggest a critical role in agonist recognition as the Y 1 R mutant Y100 2.64 A displays a 284-fold decrease in potency for NPY ( Fig. 3i and Extended Data Table 2 ). Furthermore, the model reveals close contacts between L30 of NPY and I293 in ECL3 of Y 1 R and between R33 of NPY and the Y 1 R residue N299 7.32 (Fig. 4c ), which align with complementary mutagenesis data showing no further loss of function for combining mutant I293N with [N30]NPY and N299 7.32 A with [A33]NPY ( Fig. 3j -m and Extended Data Table 4a ).
Previous studies have shown that different NPY receptors behave differently when binding to the N terminus of NPY. Y 2 R and Y 5 R can bind to N-terminally truncated NPY, whereas Y 1 R and Y 4 R require the complete N terminus of NPY for full agonist potency 25, 27 . However, these data did not allow conclusions about the interaction of the N terminus of NPY with the receptor. To further explore the involvement of the NPY N terminus in recognition between the receptor and ligand, we performed mutagenesis studies, showing that truncation of the first two residues of NPY (NPY(3-36)) reduces peptide potency by more than 50-fold (Extended Data Table 4b ). This decrease in potency, however, is not seen when these residues are mutated to alanine ([A1,A2]NPY, fivefold shift in the half-maximal effective concentration (EC 50 )), suggesting important contributions of the peptide backbone in binding to the receptor. Our NPY-bound model suggests that the N-terminal region of NPY makes close contacts with the T180-F199 fragment in ECL2 of Y 1 R and is also in proximity to the receptor N terminus ( Fig. 4a, d ). To experimentally verify interacting sites in the receptor, we performed photo-crosslinking studies between NPY analogues carrying the highly reactive p-benzoyl-phenylalanine [Bpa 1 , K 4 [(Ahx) 2 -biotin]]NPY (in which Ahx denotes aminohexanoate) and Y 1 R. Crosslinked fragments were assigned to two regions in Y 1 R, the N terminus (K21-D32) and the ECL2 (A191-D205) (Extended Data Fig. 5 and Extended Data Table 5 ). Previous studies demonstrated that deletion of the Y 1 R N terminus does not interfere with receptor signalling, but reduces NPY binding by about 95% compared to the full-length receptor 29 . This creates the possibility that the N terminus of Y 1 R has a role in recognizing and positioning the peptide ligand, which is in agreement with the photo-crosslinking data. Consistent with the crosslinking hits in receptor ECL2, our mutagenesis data show that the F184A/N and V197N mutations in this region greatly reduce NPY potency (Extended Data Table 4c ). Together, these data suggest that the N terminus and ECL2 of Y 1 R have important roles in the recognition of the N terminus of NPY and receptor activation. This contrasts with NPY binding at Y 2 R, in which ECL2 may interact with the central α-helix of NPY and the peptide N terminus is flexible and not anchored by the receptor 16 . Although this study provides insights into the interactions between Y 1 R and NPY, further structural details, such as the structures of Y receptors bound to NPY, are required to fully understand the endogenous agonist-binding modes of the NPY receptor family.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Cloning and protein expression. The DNA sequence of wild-type human Y 1 R was optimized and synthesized by Genewiz and then cloned into a modified pFastBac1 vector (Invitrogen), which contains an expression cassette with a haemagglutinin signal sequence followed by a Flag tag before the receptor at the N terminus and a PreScission protease site followed by a 10 × His-tag at the C terminus. An engineered construct was generated by inserting a modified T4 lysozyme (T4L) 31 at the third intracellular loop (ICL3) between residues R241 and D250 and introducing a mutation (F129 3.41 W) 32 . Twenty-five amino acids (V359-I384) were truncated at the C terminus to further improve protein yield and stability. Bac-to-Bac Baculovirus Expression System (Invitrogen) was used to generate high-titre (> 10 8 viral particles per ml) recombinant baculovirus. Spodoptera frugiperda (Sf9) cells (Invitrogen) at a density of 2 × 10 6 cells per ml were infected by viral stock at an MOI (multiplicity of infection) of 5. As well as the virus, a ligand (UR-MK299 or BMS-193885) was added to the cell culture to a final concentration of 1 μM. Transfected cells were cultured at 27 °C for 48 h and then collected by centrifugation and stored at −80 °C until use.
Purification of Y 1 R-UR-MK299 and Y 1 R-BMS-193885 complexes.
Frozen insect cells expressing the Y 1 R-UR-MK299 complex were disrupted with thawing and repeated dounce homogenization in a hypotonic buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and protease inhibitor cocktail (Roche). After centrifugation at 160,000g for 30 min, cell debris was re-suspended in a highosmotic buffer (10 mM HEPES, pH 7.5, 1 M NaCl, 10 mM MgCl 2 , 20 mM KCl) and then homogenized extensively. Soluble and membrane associated proteins were removed from the suspension by centrifugation. This procedure was repeated two to three more times and then the hypotonic buffer was used to remove the high concentration of NaCl. Purified membranes were re-suspended in the hypotonic buffer with additional 30% (v/v) glycerol and stored at −80 °C until use.
Purified membranes were thawed on ice in the presence of 100 μM UR-MK299, 2 mg ml −1 iodoacetamide (Sigma) and EDTA-free protease inhibitor cocktail (Roche) and incubated at 4 °C for 1 h. Equal volume of solubilization buffer containing 100 mM HEPES, pH 7.5, 1 M NaCl, Data collection and structure determination. X-ray diffraction data were collected at the SPring-8 beam line 41XU, Hyogo, Japan, on a Pilatus3 6 M detector (X-ray wavelength 1.0000 Å). Crystals were exposed with a 10 μm × 8 μm mini-beam for 0.2 s and 0.2° oscillation per frame. Data from the 47 best-diffracting crystals of the Y 1 R-UR-MK299 complex and 33 crystals of the Y 1 R-BMS-193885 complex were processed by XDS 33 . The structure of the Y 1 R-UR-MK299 complex was solved by molecular replacement implemented in Phaser 34 using the receptor portion of NTS1 (Protein Data Bank (PDB) accession number 4GRV), converted to polyalanines, and T4L structure (PDB accession number 1C6P) as search models. The correct molecular replacement solution contained one Y 1 R-T4L molecule in the asymmetric unit. Initial refinement was performed with REFMAC5 35 and BUSTER 36 , and then manual examination and rebuilding of the refined coordinates were carried out in COOT 37 using both |2F o | − |F c | and |F o | − |F c | maps. The structure has been carefully refined and the Ramachandran plot analysis indicates that 100% of the residues are in favourable (95.5%) or allowed (4.5%) regions (no outliers). The final model includes 306 residues (F18-R241 and S256-F337) of the 384 residues of Y 1 R and residues N2-Y161 of T4L. The Y 1 R-BMS-193885 complex structure was solved using Y 1 R in the Y 1 R-UR-MK299 complex and T4L as search models and refined using the same procedure. The Ramachandran plot analysis indicates that 100% of the residues are in favourable (95.4%) or allowed (4.6%) regions (no outliers). The final model of the Y 1 R-BMS-193885 complex contains 301 residues (D31-R241 and D250-D339) of Y 1 R and the 160 residues of T4L. Helix VIII in the Y 1 R-UR-MK299 structure rotates towards helix VI by about 90° compared to the BMS-193885-bound structure, this is probably caused by crystal packing (Extended Data Fig. 1 ). Immunoblotting. The total solubilized protein of the Sf9 membrane preparations (see above) used in the radio ligand binding assay was determined using the Bradford method according to the manufacturers' protocol (BioRad Protein Assay; BioRad). Aliquots of homogenized membrane preparations, corresponding to 100 μg of protein, were centrifuged at 50,000 g at 4 °C for 15 min, and the pellets were re-suspended in 50 mM Tris, pH 7.4, supplemented with 1 mM EDTA and protease inhibitors (SIGMAFAST Protease Inhibitor cocktail tablets, Sigma) at a protein concentration of 1,600 μg ml −1 . Membrane homogenates (15 μl) were processed and subjected to immunoblotting as described previously 38 with the following modifications: blotting onto the nitrocellulose membrane was performed at 60 mA for 60 min. Primary antibody anti-Flag M1 from mouse (Sigma, F3040, lot SLBK1592V) was diluted 1:500. The secondary antibody, an anti-mouse IgG horseradish peroxidase (HRP)-conjugated antibody from goat (Sigma, A0168, lot 080M4839) was diluted 1:80,000. The washing steps after incubation with the primary and the secondary antibody were 3 × 10 min each. Control experiments in the absence of the primary antibody were not performed. Radioligand-binding assay. All binding experiments with [ 3 H]UR-MK299 (synthesis described elsewhere 10 ) were performed on Sf9 membrane preparations in PP 96-well microplates (Greiner Bio One) at 23 ± 1 °C using a sodium-containing, iso-osmotic HEPES buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM Mg 2 SO 4 and 25 mM NaHCO 3 supplemented with 1% BSA) for competition-binding studies with antagonists, and a sodium-free, hypo-osmotic HEPES buffer (25 mM HEPES, pH 7.4, 2.5 mM CaCl 2 and 1 mM MgCl 2 supplemented with 1% BSA) for competition binding studies with the agonist NPY (hereafter, both buffers are referred to as 'binding buffer'). Before competition binding experiments, dissociation constant (K d ) values of [ 3 H] UR-MK299 were determined by saturation binding using the respective binding buffer. In the case of saturation-binding experiments, [ 3 H]UR-MK299 was 1:1 diluted with 'cold' UR-MK299 (hereafter, the mixture is referred to as 'radioligand'). On the day of the experiment, Sf9 membranes were thawed, re-suspended using a 1-ml syringe equipped with a needle (20 G) and then centrifuged at 16,000g at 4 °C for 10 min. The supernatant was discarded and the pellets were re-suspended in binding buffer using a 1-ml syringe equipped with a needle (27G3/4). The membrane homogenates were stored on ice until use. The total amount of protein per well was between 0.25 and 8 μg, depending on the receptor expression level. Saturation binding experiments. For the determination of total binding, wells were pre-filled with binding buffer (160 μl), and then 20 μl of binding buffer, containing the radioligand at a concentration tenfold higher than the final concentration, was added. For the determination of unspecific binding (in the presence of UR-MK299 at a 100-fold excess), wells were pre-loaded with binding buffer (140 μl), binding buffer (20 μl) containing UR-MK299 (tenfold concentrated) and binding buffer (20 μl) containing the radioligand (tenfold concentrated). To all wells, 20 μl of the membrane suspension were added, and the plates were shaken at 23 °C for 90 min. The membranes were collected on GF/C filter mats (0.26 mm; Whatman) (pre-treated with 0.3% polyethylenimine for 30 min) and washed with cold Tris buffer (91 g l −1 Tris base, 25.5 g l −1 MgCl 2 ·6H 2 O and 3.76 g l −1 EDTA) using a Brandel Harvester (Brandel). Filter pieces were punched out and transferred into 1450-401 96-well plates (PerkinElmer). Rotiscint eco plus (Carl Roth) (200 μl) was added, and the plates were sealed with transparent tape (permanent seal for microplates, PerkinElmer), vigorously shaken for at least 3 h and kept in the dark for at least 1 h before the measurement of radioactivity (d.p.m.) with a MicroBeta2 plate counter (PerkinElmer). Specific binding data (d.p.m.) were plotted against the free radioligand nanomolar concentration (obtained by subtracting the amount of bound radioligand (nM) (calculated from the specifically bound radioligand in d.p.m., the specific activity, and the volume per well) from the total radioligand concentration (nM)) and analysed by a two-parameter equation describing hyperbolic binding (SigmaPlot 11.0, Systat Software Inc.) to obtain K d and receptor density (B max ) values. For K d values < 1 nM, the B max was kept below 1,200 d.p.m. by choosing an appropriate protein concentration. For K d values > 1 nM, the B max was kept below 3,300 d.p.m. Competition-binding experiments. Competition-binding experiments were performed according to the procedure for saturation binding with the following modifications: [ 3 H]UR-MK299 was used undiluted and in the case of Y 1 R mutants, for which [ 3 H]UR-MK299 exhibited a K d value > 3 nM, the total volume per well was 100 μl, that is, in the case of total binding, wells were pre-filled with binding buffer (80 μl), and 10 μl of binding buffer containing [ 3 H]UR-MK299 (tenfold concentrated), and the membrane homogenate (10 μl) were added. The following concentrations of [ 3 H]UR-MK299 were used for competition binding with antagonists: 0.2 nM (wild-type Y 1 R, T280 6.52 A, T212 5.39 A), 0.3 nM (F173 4.60 W), 1.1 nM (L279 6.51 A), 5 nM (Q219 5.46 A), 7 nM (L215 5.42 G), 10 nM (I124 3. 36 A, F173 4.60 A). 1 nM [ 3 H]UR-MK299 was used for competition binding with NPY. The incubation time throughout was 90 min. Unspecific binding was determined in the presence of UR-MK299 (100-fold excess to [ 3 H]UR-MK299). Total binding was between 700 and 3,500 d.p.m. Maximum unspecific binding amounted to ≤30% of total binding. Specific binding data (d.p.m.) were plotted against log(concentration of competitor) and analysed by a four-parameter logistic equation (log(inhibitor) versus response-variable slope, GraphPad Prism Software 5.0) to obtain pIC 50 values, which were converted to half-maximal inhibitory concentration (IC 50 ) values (pIC 50 = −log 10 (IC 50 )). In case of incomplete displacement of [ 3 H] UR-MK299 (specifically bound radioligand at the highest competitor concentration between 20% and 50%), pIC 50 values were determined by plotting log (B/(B 0 − B) ) (Hill plot; B denotes specifically bound radioligand in the presence of competitor (values between 10 and 90%), B 0 is the specifically bound radioligand in the absence of competitor (B 0 = 100%)) against log(competitor concentration) (at least three data points) and pIC 50 values (log (B/(B 0 -B) ) = 0) were determined by linear regression. K i values were calculated from the IC 50 value as well as the respective K d value (Extended Data Table 3 ) and the concentration of [ 3 H]UR-MK299 according to the Cheng-Prusoff equation 39 . Inositol phosphate accumulation assay. The signal transduction assay was performed as previously described 40, 41 . In brief, COS-7 cells (obtained from American Type Culture Collection, and species specificity verified by COI DNA barcoding) were seeded into 48-well plates and were transiently co-transfected with wild-type receptor or receptor mutant and a chimeric G protein (G αΔ6qi4myr ) plasmid DNA 42 . Cells were routinely tested for mycoplasma contamination. Cells were radioactively labelled with myo[2-3 H]inositol (Perkin Elmer) overnight, and then stimulated with an increased concentration of NPY (NPY curve). For antagonist curves, cells were stimulated with the antagonist (BIBP3226: 10 −5 M, BIBO3304: 10 −6 M, MK-HU404: 10 −7 M, UR-MK289: 10 −5 M, UR-MK299: 10 −7 M) parallel to an increased concentration of NPY for 1 h (standard conditions). After cell lysis, anion exchange chromatography was performed and isolated, radioactive accumulated inositol phosphate derivatives were analysed by liquid scintillation counting (scintillation cocktail Optiphase HiSafe, Perkin Elmer).
Using GraphPad Prism 5.0 (GraphPad Software) the determined concentration response curves were analysed. The curves were normalized to the top (100%) and bottom (0%) values of the associated NPY curve. All curves of independent experiments were summarized to one single concentration response curve by the row means total function. Using nonlinear regression (curve fit) the EC 50 and pEC 50 ± s.e.m. were examined. The shift between the NPY and NPY/antagonist curves is defined as the EC 50 ratio and calculated by dividing EC 50(NPY/antagonist) / EC 50(NPY) , the Hill slope was set to 1. All experiments were performed at least two times independently in technical duplicate. Live-cell fluorescence microscopy. The membrane localization of Y 1 R and receptor mutants was verified by fluorescence microscopy. COS-7 cells were seeded in 8-well μ-slides (IBIDItreat) and transiently transfected with Lipofectamine 2000 transfection reagent (Invivogen, Toulouse, France). Twenty-four hours after transfection, nuclei were stained with Hoechst33342 (Sigma-Aldrich) and images were recorded using an ApoTome Imaging System, AxioVert Observer Z1 (YFP: Filter Set 46, DAPI: Filter Set 49, ApoTome, 63×/1.40 oil objective, ZEISS) in a quasi-confocal setting. The data demonstrate that all the mutants are expressed at similar, and wild-type-like, level in COS-7 cells (Extended Data Fig. 2) . Quantification of receptor surface expression in COS-7 cells. COS-7 cells were seeded into black 96-well plates (Greiner), and transiently transfected with a plasmid encoding a receptor-eYFP fusion protein using MetafectenePro. Twenty-four hours after transfection, cells were washed once with HBSS, and fluorescence was quantified using a plate reader (Tecan Infinite M200, Tecan, Männedorf, Switzerland) at excitation 488/5 nm and emission 530/5 nm. Data were normalized to mock transfected (0%) and wild-type Y 1 R-eYFP (100%). Results represent mean ± s.e.m. from three independent experiments performed in quadruplicate. Peptide synthesis. Porcine NPY (YPSKPDNPGEDAPAEDLARYYSALRH YINLITRQRY-NH 2 ) and NPY analogues were synthesized by automated solid-phase peptide synthesis on an automated multiple peptide synthesis robot system (Syro, MultiSynTech), using a 9-fluorenylmethoxycarbonyl-tert-butyl (Fmoc/tBu) strategy in 15 μM scale as previously described 43 . NPY-tyramide was synthesized as previously described 44 . Isotopically labelled NPY variants were prepared as described 16 , and 13 C/ 15 N-labelled amino acids were coupled manually with 2 equivalents (equiv.) hydroxybenzotriazole/ N,N′-diisopropylcarbodiimide (DIC) in DMF overnight. The porcine variant of NPY, which contains a single mutation M17L was used. This variant has binding affinity and signalling properties that are identical to human NPY and will therefore be referred to as wild-type NPY 45 . It also has increased solubility to assist in handling.
Modified NPY analogues [Bpa 1 , K 4 [(Ahx) 2 -biotin]]NPY and [K 4 [(Ahx) 2biotin]]NPY were synthesized by automated solid-phase peptide synthesis and Bpa, Ahx and biotin were coupled manually using orthogonal 1-(4,4-dimethyl-2,6dioxocyclohexylidene)ethyl (Dde) protection groups, cleaved by freshly prepared 3% (v/v) hydrazine in DMF for 10 × 5 min. Manual coupling reactions were performed by incubation of the resin with 5 equiv. of the respective amino acid, 5 equiv. HOBt and 5 equiv. DIC in DMF for 2 h.
For biotin labelling, 3 equiv. biotin was dissolved in DMF for 10 min at 60 °C. Next, 3 equiv. HOBt and 3 equiv. DIC were added to the mixture. Coupling was performed overnight at room temperature under constant shaking. Bpa containing peptides were cleaved from the resin and completely deprotected with a mixture of trifluoroacetic acid (TFA)/thioanisole (TA)/water (90:5:5 v/v/v).
All peptides were purified by preparative reversed-phase high-performance liquid chromatography (RP-HPLC) on a Jupiter 4 u Proteo RP-C18 column (90 Å, 4 μm, Phenomenex), Kinetex 5 u XB-C18 column (100 Å, 5 μm, Phenomenex), Kinetex 5 u Biphenyl (100 Å, 5 μm, Phenomenex), Aeris 3.6 μm WIDEPORE XB-C18 (200 Å, 3.6 μm, Phenomenex) or Varitide RPC (200 Å, 6 μm, Agilent Technologies). All peptides were characterized by matrix-assisted laser desorption/ ionization time of flight (MALDI-TOF) mass spectrometry (Ultraflex III MALDI-TOF/TOF, Bruker daltonics) and ESI-HCT (high-capacity ion trap electrospray-ionization mass spectrometry, Bruker Daltonics). Peptide purities were determined by two different analytical RP-HPLC systems using 0.1% (v/v) TFA in H 2 O (eluant A) and 0.08% (v/v) TFA in acetonitrile (ACN) (eluant B). Purity of all peptides was ≥ 95%. NMR measurements of Y 1 R-bound NPY. Fourteen differently isotopically labelled [U-13 C/ 15 N]porcine NPY peptides were prepared by standard fluorenylmethyloxycarbonyl (Fmoc) solid-phase synthesis as described previously 16 . On the basis of the structure of micelle-bound NPY, the positions of the NMR labels were chosen to avoid signal overlap in 13 C-13 C single quantum/double quantum correlation experiments and to allow straightforward signal assignment.
Expression of the human Y 1 R in Escherichia coli as inclusion bodies, inclusion body preparation, solubilization of the receptor in SDS and receptor purification were as described 46 yielding ~40-50 mg Y 1 R per litre of expression medium. To assemble the Y 1 R into a functional state, a three-step folding protocol was applied. In step 1, the purified Y 1 receptor was dialysed against a degassed buffer containing 2 mM SDS, 50 mM NaP, pH 8.5, 1 mM EDTA, 1 mM reduced glutathione, and Letter reSeArCH 0.5 mM oxidized glutathione at room temperature for 48 h. Subsequently, 25% (w/w) poly(ethylene glycol) (molecular mass 20 kDa) was added to the buffer to concentrate the receptor before reconstitution. In step 2, bicelles consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC-c7) (AvantiPolarLipids) with a q value of 0.25 in 50 mM NaP, pH 8.0 were incubated with Y 1 R, with three subsequent cycles of fast temperature cycles from 42 °C to 0 °C. Aggregated protein was removed instantly by centrifugation. In step 3, the Y 1 R samples were concentrated in large bicelles (q > 20), which were used instead of liposomes because of the high achievable receptor packing 46 . In large bicelles, all receptor binding sites are fully accessible. Subsequently, 50 mg ml −1 BioBeadsSM2 was added at least twice to the solution. After removal of the beads with a sieve, samples were washed four times through cycles of pelleting by centrifugation and resolubilization in 50 mM NaP, pH 7.0. Concentration determination of the membrane embedded receptor was performed by solubilization of the bicelles in ten times the volume of 15 mM SDS and 50 mM NaP, pH 7.0 and subsequent measurement of the Y 1 R intrinsic absorption at 280 nm using UV-visible spectroscopy. Labelled NPY variants in a slight molar excess were added to the Y 1 R after detergent removal but before concentrating.
Assessment of the binding affinity of the Y 1 R was carried out using homogenous fluorescence assays as described in the literature 47 . The reconstituted receptor was incubated in increasing concentrations with 50 nM fluorescently labelled NPY (NPY-atto520) overnight at room temperature in 50 mM NaP, pH 7.0 and 0.1% BSA. The fluorescence spectra were recorded on a FluoroMax-2 (JOBIN YVON) in a 10 mm quartz cuvette at 20 °C. The maximum signals of each spectrum were determined, normalized and plotted against the receptor concentration. The inflection point for Y 1 R binding was determined (OriginPro 8 G / DoseResp) at EC 50 = 52 nM, demonstrating high functionality of the system. As a control, we used empty bicelles in concentrations that matched the bicelle concentration of the receptor samples, resulting in a lower binding ability to the ligand in comparison to the Y 1 R.
NMR spectra were recorded on a Bruker Avance III 600 NMR spectrometer. The 13 C cross-polarization magic angle spinning (MAS) NMR experiments (0.7 ms contact time) were carried out using a double-resonance MAS probe with a 4 mm spinning module. Typical 90° pulse lengths were 4 μs for 1 H and 13 C and heteronuclear decoupling (SPINAL64) at a field strength of ~65 kHz. The 13 C chemical shifts were referenced relative to tetramethylsilane. The experiments were conducted at −30 °C and an MAS frequency of 7 kHz. The 13 C double quantum 13 C single quantum correlation spectra were acquired using the SPC-5 recoupling sequence 48 for double quantum excitation and reconversion (set to 0.571 ms each). The relaxation delay was 2.4 s. Molecular docking of NPY into Y 1 R. Peptide docking of full-length porcine NPY was completed using Rosetta's FlexPepDock application 49 . In brief, low energy backbone conformations were generated from the starting conformation of UR-MK299-bound Y 1 R. Initially, the trimer of C-terminal NPY was docked into these conformations using full flexible docking guided by mutagenesis data. For each round of docking 5,000 models were generated. The models were sorted by total energy and binding energy. Top models from a given docking round were used to seed the next round of docking in which the peptide was extended. Fragment picking was performed using the fragment_picker application within Rosetta 26 . Secondary structure during fragment picking was guided by the NMR chemical shift data. Additionally, experimentally derived restraints were used to guide docking (R35-D287 6.59 , R35-N283 6.55 , Y36-Y100 2.64 , R33-N299 7.32 , L30-I293 ECL3 ). After docking peptides of length 6, 12, 18 and 36, the binding pocket was resampled to allow the ligand binding pocket to adapt to the shape of the peptide. This was accomplished with RosettaCM 50 . The Y 1 R crystal structure was used as a template along with the docked model to ensure the models did not drift too far from the starting structure though the N terminus was removed until the last docking step to provide steric bulk. Following full-length NPY docking, the N terminus of NPY was localized using loose distance constraints with the peptides identified in crosslinking experiments. Model selection from RosettaCM was accomplished using clustering to ensure backbone diversity. Following the identification of docked poses that satisfied the majority of experimental data, the chemical shifts of docked NPY peptides were calculated and filtered against the experimental NMR data to generate a final ensemble of docked poses with a 1.4 p.p.m. root mean square distance to the experimental data. To analyse the binding interactions, per residue energetic analysis was calculated using the residue_energy_breakdown algorithm. The model with the lowest energy was selected as the representative binding pose (Fig. 4a) . The ensemble is rather tight and therefore the individual binding poses are similar in overall structure (Fig. 4b) .
Photo-crosslinking experiment between Y 1 R and NPY N terminus. Cell-free expressed Y 1 R was produced by coupled in vitro transcription-translation performed as previously described 51 using a bacterial cell lysate (S30 extract) from E. coli BL21 (DE3). Soluble membrane protein expression was achieved by addition of 0.1% (w/v) Brij-58, 1 mM oxidized glutathione (GSSG) and 5 mM reduced glutathione (GSH). Expression buffer was then exchanged to a binding buffer (0.1 M Tris/HCl, pH 7.4, 5% glycerol and 0.1% (w/v) Brij-58) and samples were purified by ligand affinity chromatography using [K 4 [(Ahx) 2 -biotin]]NPY immobilized on Pierce Avidin Agarose beads (Thermo Fisher Scientific) as previously described 52 . Elution was performed using 60 mM CaCl 2 .
For photo-crosslinking Y 1 R in binding buffer was incubated with [Bpa 1 , K 4 [(Ahx) 2 -biotin]]NPY in a molar ratio of 4:1 (5 nmol:1.25 nmol) for 30 min at room temperature. In addition, the same reaction was performed with an eightfold-excess of NPY (Y 1 R:[Bpa 1 , K 4 [(Ahx) 2 -biotin]]NPY:NPY, 4:1:8). Subsequently, the opened reaction vessels were placed on ice and irradiated with UV light (UV lamp, Atkas Fluorest forte, λ = 366 nm, 180 W) for 90 min. 50 μl of photo-crosslinked Y 1 R sample (~200 μg) was digested with Glu-C and rLys-C (Promega) according to the manufacturer's protocol. Crosslinked fragments were then isolated by affinity purification using Monomeric Avidin Agarose beads (Thermo Fisher Scientific) according to the manufacturer's protocol. Possible fragments of digested Y 1 R were calculated using the online tool PeptideMass 53 . To account for incomplete digestion the tool allowed for a maximum of five missed cleavages. For the analysis the combined option 'Glu C (phosphate) + Lys-C' was chosen. The same procedure was used for the calculation of possible NPY fragments. Theoretical masses of fragments after enzymatic cleavage of photocrosslinked Y 1 R-[Bpa 1 , K 4 [(Ahx) 2 -biotin]]NPY were calculated by adding possible Y 1 R fragment masses to NPY fragment masses containing the N terminus. The masses of Bpa, two times Ahx and biotin reduced by water were added manually to account for the formation of a peptide bond. Peptide fragments of photocrosslinked Y 1 R were analysed by MALDI-TOF mass spectrometry using an Ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics).
Functionality of cell-free expressed Y 1 R samples was verified by a homogenous binding assay based on fluorescence polarization. We used [Dpr22-Atto 520]NPY (hereafter: NPY-Atto 520) as a fluorescence tracer (inositol phosphate accumulation in transiently transfected COS-7: EC 50 = 24 nM, pEC 50 = −7.61 ± 0.20). 50 nM of NPY-Atto 520 was incubated with increasing concentrations of Y 1 R in Brij-58 micelles in buffer (0.1 M Tris/HCl, pH 7.4, 2.5% glycerol, 0.1% (w/v) Brij-58 and 0.1% bovine serum album) for 90 min under gentle agitation in opaque 96-well plates. Fluorescence was then measured in a Tecan Spark plate reader (Tecan) using linear polarized light (excitation 510/5 nm, emission 550/10 nm, 90° detection angle). Experiments were conducted at least twice independently in duplicate. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. Atomic coordinates and structure factor files for the Y 1 R-UR-MK299 and Y 1 R-BMS-193885 complex structures have been deposited in the Protein Data Bank (PDB) with accession codes 5ZBQ and 5ZBH, respectively. Data Table 5 ). Experiments were repeated twice independently with similar results, and only fragments that were observed in both experiments are listed here and in Extended Data Table 5 . c, Binding of Atto 520-labelled NPY (50 nM) to increasing amounts of cell-free produced Y 1 R in Brij-58. Data reflect fluorescence enhancement upon binding. An EC 50 value of 69 nM was determined. Data shown are mean ± s.e.m. from six independent experiments performed in technical triplicate. c(Y 1 R), concentration of Y 1 R.
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Extended data table 4 | Inositol phosphate accumulation assays of wild-type and mutant Y 1 receptors for NPY and NPY analogues nd, not determined up to 10 −4 M agonist concentration; /, not tested. *Peptides were synthesized as described in the 'Peptide synthesis' section of the Methods. †EC50 values were determined using GraphPad Prism 5.0. All curves were normalized to the top and bottom values of the Y1R-NPY curve. Nonlinear regression (curve fit) was performed for normalized response in all assays. All data are shown as mean values from at least three independent experiments or results of two individual experiments each performed in technical duplicate.
‡The EC50 shifts were determined by EC50(mutant)/EC50(wild type). The Hill slope was set to one. For the wild-type receptor x-fold (fold change) is set to one. A lower EC50 shift of the NPY analogue/mutant compared to NPY/mutant was interpreted as no further loss of function and a direct interaction between both positions. §Sample size; the number of independent experiments performed in technical duplicate. ||Previously published data 27 
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Experimental design 1. Sample size
Describe how sample size was determined.
Due to radiation damage, X-ray diffraction data collection of the protein crystals was limited to 5-10 degree per crystal. To collect a complete data set for structure determination, diffraction data from multiple crystals were integrated and scaled using XDS. By calculating completeness of the data set, diffraction data from 47 Y1R-UR-MK299 crystals and 33 Y1R-BMS-193885 crystals were used to ensure the completeness was close to 100%. For the ligand binding, IP accumulation assays and NMR measurements, 2-5 independent experiments were performed in technical duplicate/ triplicate to ensure each data point was repeatable.
Data exclusions
Describe any data exclusions.
No data were excluded from the analyses.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization is not relevant to this study, as protein and crystal samples are not required to be allocated into experimental groups in protein structural studies, and no animals or human research participants are involved in this study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding is not relevant to this study, as protein and crystal samples are not required to be allocated into experimental groups in protein structural studies, and no animals or human research participants are involved in this study. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons Test values indicating whether an effect is present Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Phaser: version 2.5.6 (CCP4Interface 6.5.000) REFMAC5: version 5.8.0103 BUSTER: version 2.10.3 COOT: version 0.7.2 SigmaPlot 11.0: Systat Software Inc., Chicago, IL; GraphPad Prism Software 5.0: GraphPad Software, San Diego, CA For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
No unique materials were used.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). ANTI-FLAG M1 from mouse: Sigma, order no. F3040, lot SLBK1592V, diluted 1:500. anti-mouse IgG HRP-conjugated antibody from goat: Sigma, order no. A0168, lot 080M4839, diluted 1:80,000. c. Report whether the cell lines were tested for mycoplasma contamination.
The cell lines were negative for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
